Atopic Dermatitis (Eczema)
A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis
The reason for this study is to see if the study drug LY3375880 is safe and effective in adults with moderate-to-severe atopic dermatitis (AD).
The study will last about 65 weeks and may include up to 18 visits.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
- Participants must have diagnosis of AD for at least 12 months according to American Academy of Dermatology criteria
- Participants must have moderate to severe AD at screening and randomization
- Participants must have inadequate response to topical medications within 6 months of screening (or history of intolerance)
- Participants must not have concurrent treatment with topical or systemic treatments for AD